Niraparib recommended for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
In its draft guidance, NICE recommends the treatment in specific cases as an option for treating Still’s disease with moderate to high disease activity, or continued disease activity after NSAIDs or glucocorticoids.
NICE updates guidelines following a Public Health England evidence review on dependence on, and withdrawal from, prescribed medicines
Updates included in osteoarthritis, peripheral arterial disease, and low back pain and sciatica guidelines.
Updates included in eating disorders, pancreatitis and diabetes guidelines.